Trade

with

Northwest Biotherapeutics Inc
(NASDAQ: NWBO)
AdChoices
5.03
-0.06
-1.18%
After Hours :
-
-
-

Open

5.15

Previous Close

5.09

Volume (Avg)

37.61k (482.11k)

Day's Range

4.96-5.16

52Wk Range

3.10-10.64

Market Cap.

302.88M

Dividend Rate ( Yield )

-

Beta

2.99

Shares Outstanding

59.50M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 809.00k

    • Net Income

    • -65.79M

    • Market Cap.

    • 302.88M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -27,926.75

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.99

    • Forward P/E

    • -

    • Price/Sales

    • 588.24

    • Price/Book Value

    • -10.14

    • Price/Cash flow

    • -4.71

      • EBITDA

      • -64.94M

      • Return on Capital %

      • -1,488.14

      • Return on Equity %

      • -

      • Return on Assets %

      • -1,488.14

      • Book Value/Share

      • -0.50

      • Shares Outstanding

      • 59.50M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 5.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 233.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 140.76

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -27,926.75

            • 39.38

            • Net Profit Margin

            • -27,926.75

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -174,308.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 0.29

              • 2.92

              • Quick Ratio

              • 0.29

              • 2.35

              • Interest Coverage

              • -311.90

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.50

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.11

                • 196.08

                • P/E Ratio 5-Year High

                • -11.87

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.06

                • 124.82

                • Price/Sales Ratio

                • 588.24

                • 9.12

                • Price/Book Value

                • -10.14

                • 8.26

                • Price/Cash Flow Ratio

                • -4.71

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -1,488.14

                        (-6,437.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.05

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -55.47M
                      Operating Margin
                      -6,856.98
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.71
                      Ownership

                      Institutional Ownership

                      17.92%

                      Top 10 Institutions

                      13.48%

                      Mutual Fund Ownership

                      9.69%

                      Float

                      58.79%

                      5% / Insider Ownership

                      5.11%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Biotechnology Discovery

                      •  

                        1,905,504

                      • 10.38

                      • 3.18

                      • Vanguard Total Stock Mkt Idx

                      •  

                        692,054

                      • 5.60

                      • 1.16

                      • iShares Russell 2000 (AU)

                      •  

                        547,244

                      • -1.02

                      • 0.88

                      • Franklin Biotechnology Discovery Fund

                      •  

                        400,732

                      • 20.12

                      • 0.67

                      • Vanguard Extended Market Index Fund

                      •  

                        339,884

                      • 4.97

                      • 0.57

                      • iShares Russell 2000 Growth

                      •  

                        262,939

                      • -2.72

                      • 0.43

                      • CREF Stock

                      •  

                        173,225

                      • 0.00

                      • 0.29

                      • Allianz Biotechnologie

                      •  

                        169,950

                      • 0.00

                      • 0.30

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        144,240

                      • 0.00

                      • 0.24

                      • Majedie UK Smaller Companies Fund

                      •  

                        123,736

                      • 0.00

                      • 0.21

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Sabby Management LLC

                      •  

                        2,054,200

                      • -30.78%

                      • 4.50

                      • Franklin Advisers, Inc.

                      •  

                        1,088,119

                      • -56.75%

                      • 1.85

                      • Vanguard Group, Inc.

                      •  

                        975,859

                      • +15.13%

                      • 1.66

                      • BlackRock Fund Advisors

                      •  

                        876,583

                      • +903.37%

                      • 1.49

                      • Goldman, Sachs & Co.

                      •  

                        843,717

                      • +38.16%

                      • 1.44

                      • Royal Bank Of Canada

                      •  

                        515,864

                      • -0.52%

                      • 0.88

                      • State Street Corp

                      •  

                        327,945

                      • +2,502.74%

                      • 0.56

                      • Hartford Funds Management Company, LLC

                      •  

                        231,700

                      • 0.00%

                      • 0.39

                      • Geode Capital Management, LLC

                      •  

                        220,093

                      • +39.54%

                      • 0.37

                      • Susquehanna Financial Group, LLLP

                      •  

                        202,004

                      • +33.95%

                      • 0.34

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Northwest Biotherapeutics Inc was incorporated in Delaware in July 1998. The Company is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current tre...moreatments, without toxicities of the kind associated with chemotherapies, and, through a proprietary batch manufacturing process, on a cost-effective affordable basis initially in both the United States and Europe. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers which are c...moreonsidered inoperable and cannot be surgically removed. As of February 28, 2014, its Phase III clinical trial of DCVax-L in GBM is being conducted at approximately 50 sites across the United States and at one site in the United Kingdom. DCVax is a registered trademark of the Company. The Company competes with Dendreon, Celldex Therapeutics, Inc., Ark Therapeutics plc, Oxford Biomedica plc, Argos Therapeutics, Inc., Agenus, Inc., Prima Biomed, Ltd., Avax Technologies, Inc., Immunocellular Therapeutics, Ltd, among others. Its products and its ongoing development activities are subject to regulation by regulatory authorities.lessless

                      Key People

                      Ms. Linda F Powers

                      CEO/Chairman of the Board/Chief Accounting Officer/President

                      Dr. Alton L. Boynton,PhD

                      Chief Scientific Officer/Co-Founder/Director

                      Jerry J. Jasinowski

                      Director

                      Mr. Robert A. Farmer

                      Director

                      Dr. Navid Malik

                      Director

                      • Northwest Biotherapeutics Inc

                      • 4800 Montgomery Lane

                      • Bethesda, MD 20814

                      • USA.Map

                      • Phone: +1 240 497-9024

                      • Fax: -

                      • nwbio.com

                      Incorporated

                      1998

                      Employees

                      12

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: